blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2867360

EP2867360 - DESIGNED ANKYRIN REPEAT PROTEINS BINDING TO PLATELET-DERIVED GROWTH FACTOR [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  13.03.2020
Database last updated on 17.07.2024
FormerThe patent has been granted
Status updated on  05.04.2019
FormerGrant of patent is intended
Status updated on  02.08.2018
FormerExamination is in progress
Status updated on  02.01.2017
Most recent event   Tooltip01.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 03.08.2022  [2022/31]
Applicant(s)For all designated states
Molecular Partners AG
Wagistrasse 14
8952 Schlieren / CH
[2015/19]
Inventor(s)01 / BAUMANN, Michael
Agnesstrasse 8
CH-8406 Winterthur / CH
 [2015/19]
Representative(s)Latscha Schöllhorn Partner AG
Grellingerstrasse 60
4052 Basel / CH
[2019/19]
Former [2015/19]Latscha Schöllhorn Partner AG
Austrasse 24
4051 Basel / CH
Application number, filing date13731809.327.06.2013
[2019/19]
WO2013EP63488
Priority number, dateEP2012017402028.06.2012         Original published format: EP 12174020
[2015/19]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2014001442
Date:03.01.2014
Language:EN
[2014/01]
Type: A1 Application with search report 
No.:EP2867360
Date:06.05.2015
Language:EN
The application published by WIPO in one of the EPO official languages on 03.01.2014 takes the place of the publication of the European patent application.
[2015/19]
Type: B1 Patent specification 
No.:EP2867360
Date:08.05.2019
Language:EN
[2019/19]
Search report(s)International search report - published on:EP03.01.2014
ClassificationIPC:C12N15/10, C07K14/49, C07K14/71, G01N33/68
[2015/19]
CPC:
C07K14/49 (EP,KR,US); C07K14/001 (KR,US); A61P27/02 (EP,KR);
A61P27/10 (EP); A61P35/00 (KR); A61P9/14 (KR);
C07K14/47 (KR,US); C07K14/71 (EP,KR,US); A61K38/00 (KR);
C07K2318/20 (EP,KR,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2015/19]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:VON BLUTPLÄTTCHEN ABSTAMMENDER WACHSTUMSFAKTOR (PDGF)-BINDENDE, KONSTRUIERTE ANKYRIN-REPEAT-PROTEINE[2018/34]
English:DESIGNED ANKYRIN REPEAT PROTEINS BINDING TO PLATELET-DERIVED GROWTH FACTOR[2015/19]
French:LIAISON DE PROTÉINES DE RÉPÉTITION ANKYRINE SUR MESURE AU FACTEUR DE CROISSANCE DÉRIVÉ DES PLAQUETTES (PDGF)[2018/34]
Former [2015/19]DESIGNIERTE ANKYRIN-VERSTÄRKUNGSPROTEINE ZUR BINDUNG AN EINEN AUS THROMBOZYTEN GEWONNENEN WACHSTUMSFAKTOR
Former [2015/19]CONCEPTION DE PROTÉINES À MOTIFS ANKYRINE RÉPÉTÉS LIÉES AU FACTEUR DE CROISSANCE DÉRIVÉ DES PLAQUETTES
Entry into regional phase27.01.2015National basic fee paid 
27.01.2015Designation fee(s) paid 
27.01.2015Examination fee paid 
Examination procedure27.01.2015Examination requested  [2015/19]
08.10.2015Amendment by applicant (claims and/or description)
21.03.2016Despatch of a communication from the examining division (Time limit: M06)
27.09.2016Reply to a communication from the examining division
22.12.2016Despatch of a communication from the examining division (Time limit: M06)
20.06.2017Reply to a communication from the examining division
17.07.2017Despatch of a communication from the examining division (Time limit: M06)
30.04.2018Reply to a communication from the examining division
03.08.2018Communication of intention to grant the patent
21.01.2019Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time
25.03.2019Fee for grant paid
25.03.2019Fee for publishing/printing paid
25.03.2019Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  21.03.2016
Opposition(s)11.02.2020No opposition filed within time limit [2020/16]
Request for further processing for:The application is deemed to be withdrawn due to failure to fulfill actions required for granting the patent
25.03.2019Request for further processing filed
25.03.2019Full payment received (date of receipt of payment)
Request granted
03.04.2019Decision despatched
25.03.2019Request for further processing filed
25.03.2019Full payment received (date of receipt of payment)
Request granted
03.04.2019Decision despatched
The application is deemed to be withdrawn due to failure to reply to the examination report
30.04.2018Request for further processing filed
30.04.2018Full payment received (date of receipt of payment)
Request granted
16.05.2018Decision despatched
Fees paidRenewal fee
19.06.2015Renewal fee patent year 03
27.06.2016Renewal fee patent year 04
27.06.2017Renewal fee patent year 05
27.06.2018Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU27.06.2013
AL08.05.2019
AT08.05.2019
CY08.05.2019
CZ08.05.2019
DK08.05.2019
EE08.05.2019
ES08.05.2019
FI08.05.2019
HR08.05.2019
IT08.05.2019
LT08.05.2019
LV08.05.2019
MC08.05.2019
MK08.05.2019
MT08.05.2019
NL08.05.2019
PL08.05.2019
RO08.05.2019
RS08.05.2019
SE08.05.2019
SI08.05.2019
SK08.05.2019
SM08.05.2019
TR08.05.2019
IE27.06.2019
LU27.06.2019
BE30.06.2019
BG08.08.2019
NO08.08.2019
GR09.08.2019
IS08.09.2019
PT08.09.2019
[2022/31]
Former [2021/34]HU27.06.2013
AL08.05.2019
AT08.05.2019
CY08.05.2019
CZ08.05.2019
DK08.05.2019
EE08.05.2019
ES08.05.2019
FI08.05.2019
HR08.05.2019
IT08.05.2019
LT08.05.2019
LV08.05.2019
MC08.05.2019
MT08.05.2019
NL08.05.2019
PL08.05.2019
RO08.05.2019
RS08.05.2019
SE08.05.2019
SI08.05.2019
SK08.05.2019
SM08.05.2019
TR08.05.2019
IE27.06.2019
LU27.06.2019
BE30.06.2019
BG08.08.2019
NO08.08.2019
GR09.08.2019
IS08.09.2019
PT08.09.2019
Former [2021/32]HU27.06.2013
AL08.05.2019
AT08.05.2019
CY08.05.2019
CZ08.05.2019
DK08.05.2019
EE08.05.2019
ES08.05.2019
FI08.05.2019
HR08.05.2019
IT08.05.2019
LT08.05.2019
LV08.05.2019
MC08.05.2019
NL08.05.2019
PL08.05.2019
RO08.05.2019
RS08.05.2019
SE08.05.2019
SI08.05.2019
SK08.05.2019
SM08.05.2019
TR08.05.2019
IE27.06.2019
LU27.06.2019
BE30.06.2019
BG08.08.2019
NO08.08.2019
GR09.08.2019
IS08.09.2019
PT08.09.2019
Former [2021/31]AL08.05.2019
AT08.05.2019
CY08.05.2019
CZ08.05.2019
DK08.05.2019
EE08.05.2019
ES08.05.2019
FI08.05.2019
HR08.05.2019
IT08.05.2019
LT08.05.2019
LV08.05.2019
MC08.05.2019
NL08.05.2019
PL08.05.2019
RO08.05.2019
RS08.05.2019
SE08.05.2019
SI08.05.2019
SK08.05.2019
SM08.05.2019
TR08.05.2019
IE27.06.2019
LU27.06.2019
BE30.06.2019
BG08.08.2019
NO08.08.2019
GR09.08.2019
IS08.09.2019
PT08.09.2019
Former [2021/26]AL08.05.2019
AT08.05.2019
CY08.05.2019
CZ08.05.2019
DK08.05.2019
EE08.05.2019
ES08.05.2019
FI08.05.2019
HR08.05.2019
IT08.05.2019
LT08.05.2019
LV08.05.2019
MC08.05.2019
NL08.05.2019
PL08.05.2019
RO08.05.2019
RS08.05.2019
SE08.05.2019
SI08.05.2019
SK08.05.2019
SM08.05.2019
TR08.05.2019
IE27.06.2019
LU27.06.2019
BE30.06.2019
BG08.08.2019
NO08.08.2019
GR09.08.2019
PT08.09.2019
Former [2020/25]AL08.05.2019
AT08.05.2019
CZ08.05.2019
DK08.05.2019
EE08.05.2019
ES08.05.2019
FI08.05.2019
HR08.05.2019
IT08.05.2019
LT08.05.2019
LV08.05.2019
MC08.05.2019
NL08.05.2019
PL08.05.2019
RO08.05.2019
RS08.05.2019
SE08.05.2019
SI08.05.2019
SK08.05.2019
SM08.05.2019
TR08.05.2019
IE27.06.2019
LU27.06.2019
BE30.06.2019
BG08.08.2019
NO08.08.2019
GR09.08.2019
PT08.09.2019
Former [2020/21]AL08.05.2019
AT08.05.2019
CZ08.05.2019
DK08.05.2019
EE08.05.2019
ES08.05.2019
FI08.05.2019
HR08.05.2019
IT08.05.2019
LT08.05.2019
LV08.05.2019
MC08.05.2019
NL08.05.2019
RO08.05.2019
RS08.05.2019
SE08.05.2019
SK08.05.2019
SM08.05.2019
TR08.05.2019
IE27.06.2019
BG08.08.2019
NO08.08.2019
GR09.08.2019
PT08.09.2019
Former [2020/17]AL08.05.2019
AT08.05.2019
CZ08.05.2019
DK08.05.2019
EE08.05.2019
ES08.05.2019
FI08.05.2019
HR08.05.2019
IT08.05.2019
LT08.05.2019
LV08.05.2019
MC08.05.2019
NL08.05.2019
RO08.05.2019
RS08.05.2019
SE08.05.2019
SK08.05.2019
SM08.05.2019
TR08.05.2019
BG08.08.2019
NO08.08.2019
GR09.08.2019
PT08.09.2019
Former [2020/14]AL08.05.2019
AT08.05.2019
CZ08.05.2019
DK08.05.2019
EE08.05.2019
ES08.05.2019
FI08.05.2019
HR08.05.2019
IT08.05.2019
LT08.05.2019
LV08.05.2019
MC08.05.2019
NL08.05.2019
RO08.05.2019
RS08.05.2019
SE08.05.2019
SK08.05.2019
SM08.05.2019
BG08.08.2019
NO08.08.2019
GR09.08.2019
PT08.09.2019
Former [2020/12]AL08.05.2019
AT08.05.2019
CZ08.05.2019
DK08.05.2019
EE08.05.2019
ES08.05.2019
FI08.05.2019
HR08.05.2019
IT08.05.2019
LT08.05.2019
LV08.05.2019
NL08.05.2019
RO08.05.2019
RS08.05.2019
SE08.05.2019
SK08.05.2019
BG08.08.2019
NO08.08.2019
GR09.08.2019
PT08.09.2019
Former [2020/11]AL08.05.2019
AT08.05.2019
CZ08.05.2019
DK08.05.2019
EE08.05.2019
ES08.05.2019
FI08.05.2019
HR08.05.2019
LT08.05.2019
LV08.05.2019
NL08.05.2019
RO08.05.2019
RS08.05.2019
SE08.05.2019
SK08.05.2019
BG08.08.2019
NO08.08.2019
GR09.08.2019
PT08.09.2019
Former [2020/10]AL08.05.2019
AT08.05.2019
CZ08.05.2019
DK08.05.2019
ES08.05.2019
FI08.05.2019
HR08.05.2019
LT08.05.2019
LV08.05.2019
NL08.05.2019
RO08.05.2019
RS08.05.2019
SE08.05.2019
BG08.08.2019
NO08.08.2019
GR09.08.2019
PT08.09.2019
Former [2020/09]AL08.05.2019
CZ08.05.2019
DK08.05.2019
ES08.05.2019
FI08.05.2019
HR08.05.2019
LT08.05.2019
LV08.05.2019
NL08.05.2019
RS08.05.2019
SE08.05.2019
BG08.08.2019
NO08.08.2019
GR09.08.2019
PT08.09.2019
Former [2019/51]AL08.05.2019
ES08.05.2019
FI08.05.2019
HR08.05.2019
LT08.05.2019
LV08.05.2019
NL08.05.2019
RS08.05.2019
SE08.05.2019
BG08.08.2019
NO08.08.2019
GR09.08.2019
PT08.09.2019
Former [2019/50]AL08.05.2019
ES08.05.2019
FI08.05.2019
HR08.05.2019
LT08.05.2019
LV08.05.2019
NL08.05.2019
RS08.05.2019
SE08.05.2019
NO08.08.2019
GR09.08.2019
PT08.09.2019
Former [2019/49]AL08.05.2019
ES08.05.2019
FI08.05.2019
HR08.05.2019
LT08.05.2019
NL08.05.2019
SE08.05.2019
NO08.08.2019
PT08.09.2019
Former [2019/48]ES08.05.2019
FI08.05.2019
LT08.05.2019
SE08.05.2019
NO08.08.2019
PT08.09.2019
Former [2019/47]ES08.05.2019
FI08.05.2019
LT08.05.2019
NO08.08.2019
Cited inInternational search[XD]WO0220565  (UNIV ZUERICH [CH], et al) [XD] 1-7,9-19,21,23,24 * the whole document *;
 [X]WO2006050984  (SCHERING AG [DE], et al) [X] 1-7,9-19,21,23,24 * example 7; claim - *;
 [X]WO2006129828  (CANON KK [JP], et al) [X] 1-7,9-19,21,23,24 * claim -; sequence 6 *;
 [XY]WO2009068649  (GLAXO GROUP LTD [GB], et al) [X] 1-7,9-19,21,23,24 * pages 28,35,36; claims 14, 15; sequence 128 * * pages 24,25; example - * [Y] 1-7,9-19,21,23,24;
 [XD]WO2011135067  (MOLECULAR PARTNERS AG [CH], et al) [XD] 1-7,9-19,21,23,24 * the whole document *;
 [XD]  - BINZ H KASPAR ET AL, "High-affinity binders selected from designed ankyrin repeat protein libraries", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, (20040418), vol. 22, no. 5, doi:10.1038/NBT962, ISSN 1087-0156, pages 575 - 582, XP002343919 [XD] 1-7,9-19,21,23,24 * the whole document *

DOI:   http://dx.doi.org/10.1038/nbt962
 [XD]  - STUMPP M T ET AL, "DARPins: A new generation of protein therapeutics", DRUG DISCOVERY TODAY, ELSEVIER, RAHWAY, NJ, US, vol. 13, no. 15-16, doi:10.1016/J.DRUDIS.2008.04.013, ISSN 1359-6446, (20080801), pages 695 - 701, (20080711), XP023440383 [XD] 1-7,9-19,21,23,24 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.drudis.2008.04.013
 [Y]  - SHEN ET AL, "An antibody directed against PDGF receptor beta enhances the antitumor and the anti-angiogenic activities of an anti-VEGF receptor 2 antibody", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, (20070510), vol. 357, no. 4, doi:10.1016/J.BBRC.2007.04.075, ISSN 0006-291X, pages 1142 - 1147, XP022106979 [Y] 1-7,9-19,21,23,24 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.bbrc.2007.04.075
 [Y]  - HONGCHAO SHAN ET AL, "Inhibitory effect of soluble platelet-derived growth factor receptor [beta] on intraosseous growth of breast cancer cells in nude mice", CANCER SCIENCE, (20110804), vol. 102, no. 10, doi:10.1111/j.1349-7006.2011.02026.x, ISSN 1347-9032, pages 1904 - 1910, XP055035691 [Y] 1-7,9-19,21,23,24 * the whole document *

DOI:   http://dx.doi.org/10.1111/j.1349-7006.2011.02026.x
 [XP]  - PETER-CHRISTIAN KLÖHN ET AL, "IBC's 23nd Annual Antibody Engineering, 10th Annual Antibody Therapeutics International Conferences and the 2012 Annual Meeting of The Antibody Society: December 3-6, 2012, San Diego, CA", MABS, (20121203), vol. 5, no. 2, doi:10.4161/mabs.23655, ISSN 1942-0862, pages 178 - 201, XP055070468 [XP] 1-3,24-26 * page 195, column R *

DOI:   http://dx.doi.org/10.4161/mabs.23655
 [XP]  - Leonardzehr, "Molecular Partners continues to validate DARPin platform", (20120911), BioTuesdays, URL: http://biotuesdays.com/2012/09/11/molecular-partners-continues-to-validate-darpin-platform/, (20130829), XP002711999 [XP] 1-3,24-26 * page 2 *
by applicantWO9002809
 WO9308278
 WO9310214
 WO9834120
 WO9848008
 WO0032823
 WO0220565
 WO2005020972
 WO2007006665
 WO2007103515
 WO2008155134
 WO2010060748
 US2011207668
 WO2011135067
 WO2012069654
 US2013116197
    - ANDRAE, J.; GALLINI, R.; BETSHOLTZ, C., GENES DEV., (2008), vol. 22, pages 1276 - 1312
    - JO, N.; MAILHOS, C.; JU, M.; CHEUNG, E.; BRADLEY, J.; NISHIJIMA, K.; ROBINSON, G.S.; ADAMIS, A.P.; SHIMA, D.T., AM. J. PATHOL., (2006), vol. 168, no. 6, pages 2036 - 2053
    - BINZ, H.K.; AMSTUTZ, P.; P UCKTHUN, A., NAT. BIOTECHNOL., (2005), vol. 23, pages 1257 - 1268
    - BINZ, H.K.; AMSTUTZ, P.; KOHL, A.; STUMPP, M.T.; BRIAND, C.; FORRER, P.; GRÜTTER, M.G.; P UCKTHUN, A., NAT. BIOTECHNOL., (2004), vol. 22, pages 575 - 582
    - STUMPP, M.T.; BINZ, H.K; AMSTUTZ, P., DRUG DISCOV. TODAY, (2008), vol. 13, pages 695 - 701
    - FORRER, P.; STUMPP, M.T.; BINZ, H.K.; P UCKTHUN, A., FEBS LETTERS, (2003), vol. 539, pages 2 - 6
    - BINZ, H.K. ET AL., J. MOL. BIOL., (2003), vol. 332, pages 489 - 503
    - FORRER, P. ET AL., FEBS LETTERS, (2003), vol. 539, pages 2 - 6
    - TANAKA, N.; NAKANISHI, M; KUSAKABE, Y; GOTO, Y.; KITADE, Y; NAKAMURA, K.T., EMBO J., (2004), vol. 23, no. 30, pages 3929 - 3938
    - HANES, J.; P UCKTHUN, A., PNAS, (1997), vol. 94, pages 4937 - 42
    - ZAHND, C.; AMSTUTZ, P.; P UCKTHUN, A., NAT. METHODS, (2007), vol. 4, pages 69 - 79
    - TAKAHASHI, K.; SAISHIN, Y.; SAISHIN, Y.; KING, A.G.; LEVIN, R.; CAMPOCHIARO, P.A., ARCH. OPHTHALMOL., (2009), vol. 127, no. 4, pages 494 - 499
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.